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Abstract: Cannabinoids, opiates, and venoms are used in the production of pharmaceuticals; 
unfortunately, these drugs can have adverse side effects or be costly to manufacture. With our 
project, we aim to produce biological systems that make the conjugates of these pharmaceuticals 
that have less negative side-effects, lack addictive properties and are inexpensive. To achieve 
this, three protein expression systems were designed: (1) An Agrobacterium-based system in 
tobacco plants for the synthesis of CBDA synthase, (2) Engineering the pGAPz alpha vector 
system to express mambalgin in Pichia pastoris, (3) and Manufacturing the constructs of Lethal 
Toxin-Neutralizing Factor LNTF-10 and LNTF-15 which are serum derivatives of the Didelphis 
virginiana (opossum) in the pSBC13 vector for assembly in Escherichia coli.    
 
INTRODUCTION 
Each year MIT holds a synthetic biology conference in Boston, this conference is called 
the International Genetic Engineering Machines(iGEM) competition. The iGEM competition is 
an annual, worldwide, synthetic biology event aimed at undergraduate university students, as 
well as high school and graduate students. Multidisciplinary teams work all summer long to 
build genetically engineered systems using standard biological parts called BioBricks. Teams 
over the summer strive to work inside and outside the lab, to create a project that will have a 
positive contribution to their communities and the world. The GSU-iGEM team decided this year 
to create a project aimed at producing safer, more cost-effective therapeutic alternatives for chronic 
pain, epilepsy, and snake bites. 
The team decided to make the focus of the project the creation of therapeutic alternatives 
because it was observed that while individuals were suffering from various diseases are saved by 
the development and production of therapies and other health-related products created by the 
pharmaceutical industry. The factors driving human pathology continue to emerge, compound 
and diversify, and there has been a surprising lack of development to innovate and optimize 
remediation therapies (Light, BMJ).  The team decided to construct protein systems to produce 
an anti-venom synthesized from peptides found in opossums, an analgesic derived from black 
mamba venom, and THC-free form of cannabidiol (CBD) oil.  
Anti-venoms derived from snake venom are not always administered in a timely fashion 
due to the specificity of the treatment, and patients can have allergic reactions which can be just 
as deadly as the snake bite if the patient goes into anaphylactic shock. Antivenoms are also 
extremely costly to manufacture and are produced in small batches via extremely expensive 
procedures. To produce an alternative antivenom, it was decided to look for animals with natural 
immunity for a solution.    The opossum, while being the only North American marsupial, is also 
one of only a few animals on earth that are naturally able to neutralize multiple types of snake 
venom. This remarkable ability has been attributed to a series of peptides known as Lethal Toxin 
Neutralizing Factors (LTNF) (Lipps, 1999). These factors when tested in mice were found to 
completely neutralize multiple venoms as well as other toxins, such as ricin and botulism. 
Currently, the only way to obtain LTNF for experimentation is through a complicated and time-
consuming protein purification using high-pressure chromatography on Opossum Serum (Lipps, 
1999). Our plan is to take the genetic sequence for producing these peptides and clone it into E. 
coli cells for expression for generating a universal anti-venom and toxin neutralizer.   
On the market, the most efficient pain treatments rely on opioid-based drugs which are 
highly addictive narcotics. An alternative pain medication needs to be developed, to develop a 
new therapy the team decided to look to snakes instead of away from them.  Mambalgin is a 
potent analgesic protein found in the venom of the Black Mamba snake (Dendroaspis polylepis). 
Mambalgin-1, the version found here, is a 3-finger toxin consisting of 57 amino acid residues 
forming three loops around a core in the shape of a hand. This protein has been found to inhibit 
acid-sensing ion channels (ASICs) in the central and peripheral nervous systems of mice through 
intraplantar and intrathecal injections. The inhibition of ASICs – significant contributors to the 
pain pathway in both mice and humans – decreases the sensitivity of nociceptive neurons to the 
perception of pain. The potency of mambalgin has been compared to the drug morphine. Unlike 
morphine, however, mambalgin has not shown an increase in tolerance over time (Diochot et al., 
2012). Because of its potency and non-addictive properties, the potential of mambalgin as a pain 
reducer in humans is enticing. Synthetically producing this protein in large quantities would 
invalidate the need to harvest and extract directly from snakes – a dangerous and costly process. 
  
Cannabidiolic-acid (CBDA) synthase is the enzyme that catalyzes the oxidative 
cyclization of cannabigerolic-acid(CBGA) into cannabidiol acid or CBDA(Sirikantaramas, 
2004). Cannabidiol (CBD) is a non-psychotropic constituent of the fiber-type cannabis plant 
which can be found in CBD oil, and it is obtained from non-enzymatic decarboxylation of 
CBDA (Takeda et.al, 2012). It is important to produce the CBGA to CBDA pathway 
synthetically independent of cannabis plants to ensure the creation of CBD and not psychoactive 
tetrahydrocannabinol (THC). This is important because CBD oil can be used as an effective form 
of treatment for various disorders such as seizures, cancer, anxiety, post-traumatic stress 
disorder, and Crohn's disease. Since the CBDA synthase is 83.9% similar to THCA synthase in 
its 544-amino acid overlap, it should be possible to synthesize CBDA synthase in a similar 
fashion THCA synthase which has been synthesized multiple times (Sirikantaramas, 2004).  
The shift in political climate coupled with the inability of patients to pay for costly drugs 
has effectively encouraged the team to invest time in creating three bacteria based protein 
systems to produce alternative Cannabinoids, opiates, and venoms. The first system developed 
was an Agrobacterium-based system in tobacco plants for the synthesis of CBDA synthase. The 
next protein production system was engineered in the pGAPz alpha vector system to express 
mambalgin in Pichia pastoris. The final system created was to manufacture the constructs of 
Lethal Toxin-Neutralizing Factor LNTF-10 and LNTF-15 which are serum derivatives of the 
Didelphis virginiana (opossum) in the pSBC13 vector for assembly in Escherichia coli.  These 
biological systems would manufacture conjugates of these pharmaceuticals with less adverse 
side-effects, lack addictive properties, and are inexpensive.  
EXPERIMENTAL PROCEDURES 
To develop new drug therapies three protein expression systems were designed. 
CBDA synthase production system 
Cannabidiol (CBD) can be easily produced with cannabidiolic acid (CBDA) 
(Sirikantaramas, 2004). CBDA is catalyzed by an enzyme, which is called CBDA synthase, 
through oxidative cyclization. To synthesize the CBDA synthase the core enzyme in the CBD 
biosynthetic pathway the cDNA sequence for CBDA synthase was inserted into the pORE binary 
vector system. The plasmid is then transformed into Agrobacterium. The Agrobacterium 
containing the CBDA synthase is then used to transfect tobacco plant tissue with agrobacteria. 
The know transgenic tobacco plants produce CBDA synthase in their roots. The roots of these 
plants will then be introduced to CBDA synthase substrate, cannabigerolic acid, which will be 
catalyzed to form cannabidiolic acid. The Cannabidiolic acid will then be separated and heated at 
120°C for 20min to form cannabidiol. Because of the difficulties with producing CBDA 
synthase, we decided to use the same procedure to produce Horseradish Peroxidase (HRP) in the 
roots of transgenic tobacco as a proof of concept. One of the benefits of this is the 
bioluminescence that is produced when it catalyzes its substrate and allows us to prove that the 
same process could work for the production of CBDA synthase.  
Synthesis of Mambalgin protein in Pichia pastoris 
Two biological systems were developed to produce the analgesic mambalgin-1 protein. 
To create a fast growth and easy cultivation system for the mambalgin construct a production 
system was developed in the organism Escherichia coli. For E.coli system, it was necessary to 
the first codon optimized the Mambalgin-1 sequence (BBa_k1110003) for Escherichia coli using 
the IDT codon optimization tool. Restriction sites were then removed from the coding sequence 
that wasn't iGEM incompatible. An RFC 10 prefix and suffix were added, along with a start 
codon at the beginning of the sequence. Also, included in the construct was a prokaryotic RBS 
(BBa_j61101), IPTG-inducible promoter (BBa_R0011), and Myc and 6xHis epitopes. This 
fusion protein was designed specifically for easy expression in E. coli. 
For the design of the Pichia Pastorsis system, the coding sequence for mambalgin was 
taken, the TAG stop codon removed, and added RFC 25 prefix and suffix in Snapgene software 
to visualize. RFC 25 was used because we were anticipating the utilization of this part in creating 
fusion proteins. Additional nucleotides were added before the bio brick prefix and after the bio 
brick suffix to enable more efficient restriction enzyme cutting at EcoRI and PstI sites. The 
mambalgin construct was then ordered from IDT and ligated into the pSB1C3 backbone. Using 
the pGAPzα expression system provided by ThermoFisher Scientific, the GSU team has been 
working to express the protein in Pichia Pastoris. The pGAPzα vector includes the constitutive 
glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter, an alpha secretory signal peptide, 
and Myc and 6x His epitopes. The MCS, between the alpha secretion signal and epitopes, 
consists of restriction sites which will enable insertion of mambalgin. In-frame insertion into the 
MCS of pGAPza will be possible after using PCR to modify the construct - removing the RFC 
25 prefix and suffix and adding restriction sites and nucleotides. 
Creation of Lethal Toxin-Neutralizing Factor (LTNF) 
For the design of LTNF, the initial step was to codon optimized the LTNF-10 
(Bba_k1915001) and LTNF-15 (Bba_k1915003) for Escherichia coli using the IDT codon 
optimization tool. Restriction sites were then removed from the coding sequence that was not 
iGEM compatible. An RFC 10 prefix and suffix added, along with a start codon at the beginning 
of the sequence. Also, included in the construct was a prokaryotic RBS (BBa_J61101), IPTG-
inducible promoter (BBa_R0011), an HRV3C Protease Site and Myc and 6xHis epitopes. This 
protein was designed specifically for expression in E. coli.   
RESULTS 
CBDA synthase part 
The part created for CBDAs included a promoter. This part is designed for 
constitutive expression of CBDA synthase in agrobacteria. This part is a composite of the J61002 
promoter construct and our CBDAs coding sequence.  
Mambalgin part 
Expressed and characterized the mambalgin protein in E. coli. After inducing with IPTG 
overnight, the cell cultures were centrifuged and disrupted with a French press. Mambalgin was 
isolated using affinity chromatography, utilizing the 6x His tag in the construct. An SDS-PAGE 
was done, followed by a Ponceau S.  and Coomassie stain to visualize the proteins. A band was 
indicating a protein of ~9 kDa – the size of the mambalgin for E.coli construct– was seen in the 
eluate fraction. A western blot was performed using an anti-His primary antibody. This year the 
iGem team repeated this process and successfully utilized the Myc tag to further characterize the 
mambalgin protein. Protein expression was also optimized this year by varying induction time as 
well as altering concentrations of IPTG. 
 LTNF constructs 
LTNF-10 (Lethal Toxin-Neutralizing Factor) is a ten residue peptide that has been shown 
to neutralize toxins from snakes, scorpions, and bacteria. LTNF peptides were first isolated from 
opossum (Didelphis virginiana) serum. This part contains the LTNF10 peptide as well as C-term 
Myc and 6xHis tags that can be used for purification and then later removed using the HRV 
(Human Rhinovirus) protease. 
Created the inducible lac promoter+LTNF-10( Part: BBa_K1915003).This part is 
designed for inducible expression of LTNF-10 in bacteria. This part includes an IPTG inducible 
promoter, RBS J61101, and the LTNF15 peptide coding sequence. 
LTNF-15 (Lethal Toxin-Neutralizing Factor) is a 15 residue peptide. This part contains 
the LTNF-15 peptide as well as C-term Myc and 6xHis tags that can be used for purification and 
then later removed using the HRV (Human Rhinovirus) protease. 
Created the Inducible Lac promoter+LTNF-15. This part is designed for inducible 
expression of LTNF-15 in bacteria. This part includes an IPTG inducible promoter, RBS J61101, 
and the LTNF15 peptide coding sequence. 
Proof of Concept: HRP in pORE 
Horseradish peroxidase was inserted into the pORE vector and transformed into 
Agrobacterium tumefaciens. The Agrobacterium tumefaciens was used to infect tobacco plants to 
induce expression of hairy roots. To detect the horseradish peroxidase in the newly formed hairy 
roots, a chemical assay was performed. Into 5mL of deionized water( a piece of 
transformed hairy root along with 5mL of the chemical 3,3′,5,5′-Tetramethylbenzidine (TMB) 
was placed into a 15mL microcentrifuge tube. The horseradish peroxidase turned a pale blue 
color in the solution. 
FUTURE PROSPECT 
Through synthetic biology, the team created five new parts, demonstrated expression of 
two of those parts, characterized the mambalgin protein, and transformed the tobacco plants with 
an HRP reporter construct as a proof of concept for our expression of CBDAS, then detected 
expression of our reporter under real-world conditions. For each protein system, the research is 
still ongoing in order produce to biological systems that will perform as factories in the hope of 
providing a production system for inexpensive pharmaceutical derivatives. 
 To further develop the protein expression system for the Mambalgin-1 protein, the next 
steps include testing the analgesic properties in an animal model.  To produce this model, the 
team has partnered with the Neuroscience Institute at Georgia State University to create An 
Institutional Animal Care, and Use Committee (IACUC)approved the experimental protocol.   
To create THC free CBD oil, it was necessary to design a proof of concept. The plan laid 
out to prove the CBDA concept worked when the HRP enzyme in the transgenic tobacco roots 
interacted with the TMB substrate the solution turned blue! Thus, we know it is possible to insert 
CBDA synthase into the pORE vector and transform the recombinant plasmid into 
Agrobacterium to create tobacco plants that contain CBDA synthase. The presence of CBDAS 
will be confirmed with the use of mass spectrometry after purification from the aqueous 
suspension media that plants are grown in. Cannabigerol acid – the substrate for CBDAS – can 
then be added to produce cannabidiolic acid. The addition of heat to cannabidiolic acid will 
create cannabidiol. Functional testing in mammalian systems will commence after the acquisition 
of cannabidiol. Due to the lack of proper facilities in the iGEM lab for this type of chemical 
synthesis, it is necessary to collaborate with a chemistry lab.  
The LTNF constructs require further characterization of the peptide to ensure that 
construct can indeed work as a universal antivenom. To do this, we will be performing a 
bioassay to determine the reactivity of the LTNF peptide to our mambalgin protein, an element 
of the mambalgin snake venom. NMR spectroscopy will be used to characterize the LTNF 
protein further.   
In previous years, the progress of our project has been impeded by the obstacles related to 
growing and maintaining healthy plants. After having entire crops die year after year, it was 
necessary to create a reliable system. This year we developed a relatively automatic care system 
that has proven to be both efficient and fruitful in maintaining plant growth. The automated 
homemade hydroponic growth system, nicknamed the Bulbasaur Nursery, has saved team time 
and money, while simultaneously allowing for plants to become a leading chassis organism in 
the lab. The next step for our nursery is to build an aquaponics system for the growth of more 
sterile tobacco plants. 
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